PFIZER ONCOLOGY STRATEGY AND PIPELINE (AS OF AUGUST 2017)

CANCER TODAY

Despite the progress made in oncology treatment, cancer remains a complex and relentless opponent that will take the whole oncology community to tackle.

Lung cancer is the leading cause of cancer death worldwide1

An estimated 952,000 new cases of gastric cancer are diagnosed each year worldwide2

Nearly 1.1 million new cases of prostate cancer are diagnosed each year worldwide3

Nearly 412,000 people worldwide will be diagnosed with leukemia by 20202

Breast cancer is the most common cancer in women with nearly 1.7 million new cases diagnosed each year worldwide4

Approximately 338,000 new cases of kidney cancer are diagnosed each year, representing approximately 2-3% of all cancers5

References:

STRATEGIC APPROACH TO ONCOLOGY RESEARCH

At Pfizer Oncology, we are making significant investments in advancing cancer treatments with development efforts across several modalities and novel technologies, which position us to be a key player in the cancer care space.

TARGETING THE TUMOR

TARGETING THE IMMUNE SYSTEM

INNOVATIVE MODALITIES SUPPORT STRATEGY AND DRIVE FUTURE OF THERAPIES

EXPLORING MULTIPLE PATHWAYS AND TECHNOLOGIES IN ONCOLOGY

BI-SPECIFICS
DART cadherin

ANTIBODIES
aPD-L1, a4-1BB, aOX-40, aMCSF, aPD-1

ADOPTIVE T-CELLS
CAR T

SMALL MOLECULES
ALKi, IDO1i, PARPi, CDK4/6i, PI3K/mTORi, SMOi

REFERENCES:
PFIZER ONCOLOGY STRATEGY AND PIPELINE (AS OF AUGUST 2017)

PFIZER ONCOLOGY PIPELINE SNAPSHOT

Our robust pipeline of cancer therapies is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.

Pfizer’s oncology pipeline of 17 ASSETS in clinical development spans diverse mechanisms of action and novel modalities

- 17 NEW MOLECULAR ENTITIES
- 23 ADDITIONAL INDICATIONS FOR EXISTING MEDICINES
- 10 IMMUNO-ONCOLOGY ASSETS IN THE CLINIC

THE LARGEST PERCENTAGE of Pfizer R&D investment goes to oncology

- 18,000 PATIENTS are participating in ongoing clinical trials, including Pfizer-sponsored and clinical research collaboration trials

PHASE 1 | PHASE 2 | PHASE 3 | IN REGISTRATION
---|---|---|---
13 | 5 | 20 | 4

*Pipeline represents progress of Pfizer Oncology R&D programs as of August 2017. Pipeline does not represent individual assets.

ADVOCACY, COLLABORATIONS AND PARTNERSHIPS

Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s lives.

We work closely with the entire cancer community to better understand the needs of patients, families, caregivers and others impacted by cancer.

PATIENT ADVOCATES
INDUSTRY PARTNERS
PROFESSIONAL ORGANIZATIONS
POLICY MAKERS
CANCER RESEARCH FOUNDATIONS

Through these comprehensive efforts, Pfizer Oncology is helping to
Redefine Life With Cancer

© 2017 Pfizer Inc. All rights reserved August 2017